Review of recent advances in medical treatment for neuroendocrine neoplasms: somatostatin analogs and chemotherapy

Abstract

Neuroendocrine neoplasms (NENs) are a heterogeneous group of rare tumours often producing high levels of hormones and causing symptoms. There are a number of different types of NENs. They usually arise as advanced and low/intermediate grade only in a minority of cases, as high grade. Treatment depends on which type and may include surgery, interventional radiology, and systemic treatment, including chemotherapy, somatostatin analogs, interferon α2b, peptide receptor radionuclide therapy, and only for pancreatic neuroendocrine tumors, molecular targeted agents, including everolimus and sunitinib. The aim of the article is to review the medical approaches with somatostatin analogs and chemotherapy. The treatment of NENs is mainly based on their biological characteristics of aggressiveness and functional features, such as symptoms and endocrine markers.

Keywords

Neuroendocrine neoplasms / somatostatin analogs / chemotherapy / peptide receptor radionuclide therapy / molecular targeted agents

References

[1] Swarts DR,Speel EJ.Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities..Biochim Biophys Acta2012;1826:255-71

[2] WHO classification of Tumours of the Digestive System.In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors..World Heath Organization Classification of Tumours, Lyon, France: International Agency for Research on Cancer (IARC);2010;417

[3] Modlin IM,Kidd M.Review article somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours..Aliment Pharmacol Ther2010;31:169-88

[4] Yao JC,Ito T,Wolin EM,Hobday TJ,Capdevila J,Tomassetti P,Hoosen S,Lincy J,Öberg K,Third Trial (RADIANT-3) Study Group.Everolimus for advanced pancreatic neuroendocrine tumors..N Engl J Med2011;364:514-23 PMCID:PMC4208619

[5] Capdevila J,Halperin I,Yao JC.Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors..Cancer Metastasis Rev2011;30 Suppl 1:27-34

[6] Bajetta E,Fazio N,Biondani P,Ricci S,Pucci F,Bianco N,Spada F.Everolimus combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumours..Cancer2014;120:2457-63

[7] Raymond E,Raoul JL,Borbath I,Valle J,Smith D,Chen JS,Hammel P,Van Cutsem E,Lu DR,Chao R.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors..N Engl J Med2011;364:501-13

[8] Kulke MH,Meropol NJ,Ryan DP,Bergsland E,Tye L,Li JZ,Fuchs CS.Activity of sunitinib in patients with advanced neuroendocrine tumors..J Clin Oncol2008;26:3403-10

[9] Bajetta E,Valente M,Bellomo F.New perspectives in the treatment of neuroendocrine tumours..Anticancer Res2012;32:4193-200

[10] Sowa-Staszczak A,Chrzan R,Stefańska A,Kołodziej M,Pawlak D.Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)..Eir J Nucl Med Mol Imaging2011;38:1669-74 PMCID:PMC3151371

[11] Strosberg J.Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors..World J Gastroenterol2010;16:2963-70 PMCID:PMC2890935

[12] Florio T.Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatase..Mol Cell Endocrinol2008;286:40-8

[13] Florio T,carey KD,Stork PJ.Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1)..Mol Endocrinol1999;13:24-37

[14] Serri O,Kachra Z.Octreotide inhibits insulin-like growth factor-1 hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action..Endocrinology1992;130:1816-21

[15] Hoyer D,Berelowitz M,Feniuk W,O'Carroll AM,Schnbrunn A.Classification and nomenclature of somatostatin receptor..Trends Pharmacol Sci1995;16:86-8

[16] Bauer W,Doepfner W,Huguenin R,Petcher TJ.SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action..Life Sci1982;31:1133-40

[17] Bruns C,Raulf F,Schoeffter P,Lübbert H.Molecular pharmacology of somatostatin-receptor subtyes..Ann N Y Acad Sci1994;733:138-46

[18] Strosberg JR,Klimstra DS,Kulke MH,Kvols LK.The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas..Pancreas2010;39:799-800 PMCID:PMC3100733

[19] Sorbye H,Langer SW,Holt N,Dueland S,Guren MG,Birkemeyer E,Biagini M,Soveri LM,Federspiel B,Janson ET.Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma (WHO G3): the NORDIC NEC study..Ann Oncol2013;24:152-60

[20] Walter T,Cassier PA,Pilleul F,Chayvialle JA.Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors..Clin Colorectal Cancer2010;9:248-54

[21] Kulke MH,Frauenhoffer C,Ryan DP,Meyerhardt JA,Stuart K,Redston MS.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors..Clin Cancer Res2009;15:338-45 PMCID:PMC3100724

[22] Bajetta E,Procopio G,Bichisao E,Martinetti A,Verzoni E,Bajetta R.Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?.Cancer Chemother Pharmacol2007;59:637-42

[23] Berruti A,Ferrero A,Volante M,Tozzi L,Torta M,Priola AM,Amoroso V,Papotti M.Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study..BMC Cancer2014;14:184 PMCID:PMC3996907

[24] Koumarianou A,Kanakis G,Rontogianni D,Tsavaris N,Dimitriadis G.Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours..Endocr Relat Cancer2012;19:L1-4

[25] Brazeau P,Burgus E,Butcher M,Guillemin R.Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone..Science1973;179:77-9

[26] Burgus R,Butcher M.Primary structure of somatostatin, a hypotalamic peptide that inhibits the secretion of pituitary growth hormone..Proc Natl Acad Sci U S A1973;70:684-8 PMCID:PMC433335

[27] Reisine T.Molecular biology of somatostatin receptors..Endocr Rev1995;16:427-42

[28] Yamada Y,Wang K,Bell GI.Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney..Proc Natl Acad Sci U S A1992;89:251-5 PMCID:PMC48214

[29] Nilsson O,Wängberg B,Billig H,Fjälling M,Ahlman H.Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours..Br J Cancer1998;77:632-7 PMCID:PMC2149934

[30] Reubi JC,Waser B,Heitz PU,Reading CC.Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas..Cancer Res1990;50:5969-77

[31] Krenning EP,Bakker WH,Kooij PP,van Hagen M,de Jong M.Somatostatin receptor scintigraphy with 111In-STPA-D-Phe1 and 123-Tyr3-octreotide the Rotterdam experience with more than 1000 patients..Eur J Nucl Med1993;20:716-31

[32] Panzuto F,Delle Fave G.Medical treatment of gastro-entero-pancreatic endocrine tumours..In: Modlin IM, Oberg K. A century of advences in neuroendocrine tumor biology and treatment.Published by Felsenstein CCC2007;364-9

[33] Strosberg JR,Benson AB,GEPNET Treatment Consensus Panel,Broder MS,Arslan B,Gibbs JF,Iyer RV,Maples W,Strosberg J.Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process..Pancreas2013;42:397-404

[34] Rinke A,Schade-Brittinger C,Barth P,Mayer C,Pape UF,Harder J,Gress T.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID study Group..J Clin Oncol2009;27:4565-63

[35] Janson ET.Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon..Acta Oncol1993;32:225-9

[36] Kvols LK,O'Connell MJ,Rubin J.Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue..N Engl J Med1986;315:663-6

[37] Rubin J,Schirmer W,Bukowski R,Saltz L,Anthony L.Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome..J Clin Oncol 1999:17:600-6

[38] Rinke A,Schade-Brittinger C,Ronicke E,Müller HH.Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival (abstract)..ASCO meeting Abstracts2013;31:4030

[39] Sandostatin LAR Depot [prescribing information]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2011. [cited 2014 Jul 30] Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

[40] Khan MS,Davies P,Caplin ME.Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)..Aliment Pharmacol Ther2011;34:235-42

[41] O'Toole D,Bommelaer G,Bouché O,Blumberg J.Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance..Cancer2000;88:770-6

[42] Wymenga AN,Salmela PI,Van Cutsem EJ,Välimäki MJ,de Vries EG.Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hrmone-related symptoms..J Clin Oncol1999;17:1111

[43] Vinik A,Audry H.ELECT: A phase 3 study of efficacy and safety of lanreotide aurogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs) (abstract)..ASCO Meeting Abstracts2014;32:268

[44] Caplin ME,Cwikla JB,Sedlackova E,Wolin EM,Wall L,Langley A,Blumberg J.Lanreotide in metastatic enteropancreatic neuroendocrine tumors..N Engl J Med2014;371:224-33

[45] Bruns C,Briner U,Meno-Tetang G.SOM-230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile..Eur J Endocrinol2002;146:707-16

[46] Schimd HA.Pasireotide (SOM230): development, mechanism of action and potential applications..Mol Cell Endocrinol2008;286:69-74

[47] Ben-Shlomo A.Pasireotide -- a somatostatin analog for the potential treatment of acromegaly, neurendocrine tumors and Cushing's disease..IDrugs2007;10:885-95

[48] Modlin IM,Latich I,Shapiro MD.Current status of gastrointestinal carcinoids..Gastroenterology2005;128:1717-51

[49] Yao JC,Phan A,Leary C,Abdalla EK,Vauthey JN,Evans DB.One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States..J Clin Oncol2008;26:3063-72

[50] Lepage C,Coleman MP.Survival from malignant digestive endocrine tumors in England and Wales: a population-based study..Gastroenterology2007;132:899-904

[51] Pape UF,Mueller-Nordhorn J,Böhmig M,Koch M,Wiedenmann B.Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours..Endocr Relat Cancer2008;15:1083-97

[52] Modlin IM,Chung DC,de Herder WW,Caplin M,Kaltsas GA,Moss SF,Rindi G,Ruszniewski P.Gastroenteropancreatic neuroendocrine tumours..Lancet Oncol2008;9:61-72

[53] Bosman FT,Hruban RH,editors.World Health Organization Classification of Tumours..Pathology and Genetics. Tumors of the Digestive System. Lyon: IARC Press,2010;

[54] Travis WD,Muller-Hermelink HK.Pathology and genetics of tumors of the lung, pleura, thymus and heart..Geneva: IARC Press,2004;

[55] Moertel CG,O'Connell MJ.Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms..Cancer1991;68:227-32

[56] Mitry E,Ducreaux M,Rufié P,Aparicio T,Elias D,Schlumberger M.Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin..Br J Cancer1999;81:1351-5 PMCID:PMC2362979

[57] Fjällskog ML,Welin SL,Oberg KE,Eriksson BK.Treatment with cisplatin and etoposide in patients with neuroendocrine tumors..Cancer2001;92:1101-7

[58] Iwasa S,Okusaka T,Ikeda M,Tanaka T,Mitsunaga S,Hagihara A.Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas..Jpn J Clin Oncol2010;40:313-8

[59] Lu ZH,Lu N,Li J,Wang XC,Gao J,Shen L.Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas..Med Oncol2013;30:664

[60] Vélayoudom-Céphise FL,Foucan L,Chougnet CN,Malka D,Goere D,Caramella C,Planchard D,Ducreux M,Baudin E.Are G3 ENETS neuroendocrine neoplasms heterogeneous?.Endocr Relat Cancer2013;20:649-57

[61] Heetfeld M,Olsen IH,Borbath I,Barriuso J,O'Toole D.Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms..Endocr Relat Cancer2015;22:657-64

[62] Hentic O,Couvelard A,Zappa M,Maire F,Gillet A,Ruszniewski P.FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3..Endocr Relat Cancer2012;19:751-7

[63] Welin S,Sebjornsen S,Busch C.Clinical effect of temozolomide- based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy..Cancer2011;117:4617-22

[64] Kouvaraki MA,Hoff P,Evans DB,Yao JC.Fluorouracil, doxorubicin, and streptozotocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas..J Clin Oncol2004;22:4762-71

[65] Bajetta E,Carnaghi C,Ferrari L,Regalia E,Procopio G.5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors..Cancer1998;83:372-8

[66] Strosberg JR,Choi J,Coppola D,Helm J.First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas..Cancer2011;117:268-75 PMCID:PMC4665634

[67] Cassier PA,Bohas CL,Perol M,Chayvialle JA,Hervieu V.Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas..Cancer2009;115:3392-9

[68] Spada F,Marconcini R,Antonuzzo A,Di Costanzo F,Gelsomino F,Nobili E,Cella CA,Pisa E,Fazio N.Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors..Neuroendocrinology 2016 Jan 21

[69] Brizzi MP,Ferrero A,Volante M,Birocco N,Perroni D,Alabiso O,Bertetto O,Dogliotti L.Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network..BMC Cancer2009;9:388 PMCID:PMC2776604

[70] Ceppi P,Ferrero A,Rapa I,Berruti A,Scagliotti GV.Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors..Clin Cancer Res2008;14:1059-64

[71] Lim E,Nicholson G,Jett JR,Bomaji J,Asamura H,Baudin EE,Kwekkeboom D,Crowley J.Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007..J Thorac Oncol2008;3:1194-201

[72] Crona J,Welin S,Öberg K.Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre..Lung Cancer2013;79:289-93